EXCLUSIVE: Mira Pharmaceuticals Tells Benzinga 'Advancing Ketamir-2 Into Clinical Trials as Quickly as Possible Reflects Our Strategic Focus on Generating Proof-of-concept Data That Positions MIRA for a Potential M&A Transaction or Strategic Partnership'
EXCLUSIVE: Mira Pharmaceuticals Tells Benzinga 'Advancing Ketamir-2 Into Clinical Trials as Quickly as Possible Reflects Our Strategic Focus on Generating Proof-of-concept Data That Positions MIRA for a Potential M&A Transaction or Strategic Partnership'
獨家：Mira製藥公司告訴Benzinga，'儘快將Ketamir-2推進臨床試驗反映了我們在生成概念驗證數據方面的戰略重點，這爲MIRA進行潛在的併購交易或戰略合作奠定了基礎。'
EXCLUSIVE: Mira Pharmaceuticals Tells Benzinga 'Advancing Ketamir-2 Into Clinical Trials as Quickly as Possible Reflects Our Strategic Focus on Generating Proof-of-concept Data That Positions MIRA for a Potential M&A Transaction or Strategic Partnership'
獨家：Mira製藥公司告訴Benzinga，'儘快將Ketamir-2推進臨床試驗反映了我們在生成概念驗證數據方面的戰略重點，這爲MIRA進行潛在的併購交易或戰略合作奠定了基礎。'
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間